RNA vaccines train the immune system in a similar way to traditional vaccines, but they use a different strategy to get there ...

(Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Morgan Stanley lowered the firm’s price target on Moderna (MRNA) to $32 from $39 and keeps an Equal Weight rating on the shares. The firm ...

The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present ...

We recently published a list of Jim Cramer Says Wait A Little & Discusses These 11 Stocks. In this article, we are going to ...

Learn more about whether Moderna, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Moderna, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The FDA has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until ...

However, in the later stages of the pandemic, demand for the product declined, and Moderna shifted to a loss. For example, ...